Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal Tumors
10.3971/j.issn.1000-8578.2025.24.1051
- VernacularTitle:消化道肿瘤中免疫检查点药物治疗瓶颈的思考
- Author:
Chun HAN
1
;
Li BAI
2
Author Information
1. Outpatient Chemotherapy Center, Beijing Arion Cancer Center, Beijing 102600, China.
2. Department of Oncology, First Medical Center, General Hospital of Chinese People’s Liberation Army (PLA), Beijing 100853, China.
- Publication Type:SPECIALFEATURE
- Keywords:
ICIs;
Gastrointestinal tumors;
Tumor microenvironment (TME);
Inflammation;
Gut microbiota
- From:
Cancer Research on Prevention and Treatment
2025;52(7):539-547
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs), as one of relatively advanced antitumor treatment methods in recent years, have achieved significant therapeutic effects in the treatment of multiple systemic tumors. However, their application in gastrointestinal tumors is not satisfactory, with treatment bottlenecks. This article summarizes the challenges and possible solutions faced by ICIs in the treatment of gastrointestinal tumors to help clinicians better understand the limitations and future development directions of ICIs and thus develop more effective treatment strategies.
